Medindia LOGIN REGISTER
Medindia
Advertisement

ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products

Wednesday, February 27, 2008 General News
Advertisement
MONTREAL, Feb. 26 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc.("ProMetic") (TSX:PLI) announced today that it has signed the definitiveagreement for development of two hyperimmunes with Kedrion S.p.A. ("Kedrion").
Advertisement

Terms of this agreement call for upfront and milestone payments, as wellas service fees to ProMetic. Potential revenues to ProMetic from Hepatitis BHyperimmune direct sales in North America are to exceed $30 M annually, whichare expected to commence in 2011.
Advertisement

The first product to be developed will target the Hepatitis B Hyperimmunemarket which is currently estimated in Europe and in the U.S. to be at $200 Mand is expected to be at $400 M by 2015.

Kedrion has in-licensed ProMetic's technologies for the manufacturing ofhyperimmune products in Europe. Royalties, licensing and service fees for thesales of products in Europe will be paid by Kedrion to ProMetic with ProMeticretaining the commercial rights for the fully developed hyperimmune productsfor the North American market. ProMetic will in turn pay Kedrion royalties onits sales of the hyperimmune products in North America.

The product development program, including the clinical trial designed tomeet U.S. and European regulatory requirements will be funded by Kedrion, whowill be the holder of the products registration for both markets.

"This agreement with Kedrion will leverage ProMetic's ability to penetrateinto the North American hyperimmune product market and expand on our existingrevenue base," commented Mr. Pierre Laurin, President and Chief ExecutiveOfficer of ProMetic.

More about Hepatitis B

HB, hepatitis B IVIG is primarily used in preventing reinfection withhepatitis B in HBV positive liver transplant patients. It is also used in thetreatment of acute exposure to hepatitis B following acute exposure to bloodcontaining HBsAg, perinatal exposure of infants born to HBsAg-positivemothers, sexual exposure to HBsAg positive persons, and household exposure ofinfants to persons with acute hepatitis B virus infection. The groups usuallyconsidered at risk are hepatitis B researchers and workers, and many healthcare professionals.

More about Kedrion S.p.A.

Kedrion (www.kedrion.com) is a biopharmaceutical company specialized inthe development, production, commercialization and distribution ofplasma-derived products. Born in 2001 following the rationalisation andupgrading of other companies working in this field, it acquired a heritage ofexpertise that secures it a prominent role in Italy, in Europe and in theworld. Kedrion is present in over 40 countries. It's head office is inTuscany, Castelvecchio Pascoli, near Lucca.

In Italy, Kedrion is a partner of the National Health Service for theproduction of plasma-derived medicinal products. In addition, its expertiseserves other strategic partnerships with health institutions in othercountries.

Kedrion's activities are carried on through different companies and threeauthorized production plants: Bolognana, near Lucca (Tuscany); S. Antimo, nearNaples; Godollo, near Budapest. Kedrion works in four business areas:production and commercialization of plasma-derived products obtained from theplasma fractionation process; commercialization of flu vaccines and syntheticpharmaceutical products; plasma collection and commercialization in foreignmarkets; other activities, among them in particular transfer of technologicalknow-how. The three principal types of plasma-derived products produced byKedrion are: standard and hyperimmune immunoglobulin, albumin and coagulationfactors (procoagulants and anticoagulants).

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. (www.prometic.com) is a biopharmaceuticalcompany specialized in the research, development, manufacture and marketing ofa variety of commercial applications derived from its proprietary Mimet
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close